news.cmlviz.com
menu
share

Stock Volatility Risk Alert: Conatus Pharmaceuticals Inc Stock Volatility Hits An Escalated Level




Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Stock Volatility Hits An Escalated Level

Date Published:

Stock Risk Alert
Before we cover the full analysis we make a quick alert here that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has seen its stock price whip around at a notable high level. We'll go through the details below -- but that's the lede -- the stock has been moving and the market's reaction is like a yellow post it note on the face of the ticker that reads "this is not equilibrium" with an HV20 of 87.59% verus the HV20 of the S&P 500 at 6.43%.



Another bit to this risk alert, which we cover in the article, is that while the historical volatility may be a notable high level (the stock has been whipping around), the real question that needs to be answered for option traders is not if the HV20 is high, but rather if the implied volatility that is priced for the next 30-days accuratley reflects what we're about to see in the stock for the next month.

To jump forward and examine if owning or shorting options has been a positive trade in Conatus Pharmaceuticals Inc, you can go here: Getting serious about option trading.

PREFACE
This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Conatus Pharmaceuticals Inc (NASDAQ:CNAT) . We examine the little used gem of daily stock volatility over a 20-day and 30-day trading period, as well as comparisons to the last year and the actual stock returns over the last three- and six-months and the S&P 500 and Nasdaq 100 indices.


Option trading isn't about luck -- this four minute video will change your trading life forever: Option Trading and Truth


As a heads up, in the "Why This Matters" section at the end of this article on Conatus Pharmaceuticals Inc (NASDAQ:CNAT) , we're going to take a step back and show really clearly that there is actually a lot less "luck" in successful option trading than most people are aware of. This idea of an "option trading expert" is vastly over complicated so those with the information advantage can continue to profit at the expense of the rest.

But before that, let's turn back to CNAT. Here are the exact steps that led us to this rating, and whether it's a risk alert or a holding pattern.

CNAT Recent Stock Volatility


Rating
Stock volatility using proprietary measures has hit a notable high level.

Volatility Alert
Conatus Pharmaceuticals Inc is a micro cap biotechnology-pharmaceutical company with zero revenue making it essentially the risikist equity asset possible. CNAT is susceptible to extreme volatility due to FDA drug trial, new government pricing rules, results and especially takeover rumors. Here is a rolling annual volatility chart of the biotech index (IBB) versus the Nasdaq 100 and the S&P 500. Note how elevated the biotechnology sector volatility is (the pink curve) relative to the S&P 500.



Let's take a deep dive into some institutional level volatility measures for Conatus Pharmaceuticals Inc (NASDAQ:CNAT) .

Conatus Pharmaceuticals Inc Stock Performance
CNAT is up +64.4% over the last three months and up +292.7% over the last six months. The stock price is up +166.9% over the last year. The current stock price is $7.58.

CNAT Step 1: Stock Returns
The one-year stock return does not impact the volatility rating since we are looking at a shorter time horizon. However, the rating does examine the 3-month returns and the absolute difference between the 3-month and 6-month returns.

  The 3-month stock return of +64.4% has a very large impact on the stock volatility rating for CNAT.
  The enormous difference between the 3-month and 6-month stock returns has a substantial impact on the stock volatility rating for CNAT.

CNAT Step 2: Daily Stock Volatility Level
The HV30® takes the stock's day to day historical volatility over the last 30-days and then annualizes it. The HV20 looks back over just 20-days -- a shorter time period. Here is the breakdown for Conatus Pharmaceuticals Inc (NASDAQ:CNAT) and how the day-by-day stock historical volatilities have impacted the rating:

  The HV20 of 94.0% is quite high and has a significant impact on CNAT's volatility rating.


CNAT Step 3: Conatus Pharmaceuticals Inc HV20 Compared to Indices
* The HV20 for CNAT is substantially larger than that for both the S&P 500 and the NASDAQ 100 which raises the volatility rating.

* The HV20 for CNAT is substantially larger than that for the Health Care ETF (XLV) which raises the volatility rating.

Here is summary data in tabular and chart format.

           CNAT
           HV20    
   S&P 500
HV20
   NASDAQ 100
HV20   
   XLV
HV20   
           94.0%    6.43%    6.07%    5.57%

CNAT Step 4: Daily Volatility Percentiles and Highs
We also examine the annual high of the HV30 in our rating.

  The 52 week high in HV30 for Conatus Pharmaceuticals Inc is 288.5%, which is extremely high and has a large upward impact on the stock volatility rating.

Here is summary data in tabular and chart format.

           CNAT
           HV20    
   CNAT
HV30
   CNAT
HV30 High   
           94.0%    87.6%    288.5%

Final Stock Volatility Percentile Level: CNAT
The final evolution of the volatility rating for Conatus Pharmaceuticals Inc is a comparison of the HV30 value relative to its past, which is neatly summarized in the percentile -- a scoring mechanism that goes from a low of 1 to a high of 100.

  The HV30 percentile for Conatus Pharmaceuticals Inc is 19%, which means the stock has seen very low volatility in its price movement relative to its own past and that has a dampening impact on the stock volatility rating.

Conatus Pharmaceuticals Inc Realized Volatility Percentiles